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Background: Care homes have been disproportionately affected by the COVID-19 pandemic. We investigated
the potential role of asymptomatic infection and silent transmission in London care homes that reported no
cases of COVID-19 during the first wave of the pandemic.
Methods: Five care homes with no cases and two care homes reporting a single case of COVID-19 (non-out-
break homes) were investigated with nasal swabbing for SARS-CoV-2 RT-PCR and serology for SARS-CoV-2
antibodies five weeks later. Whole genome sequencing (WGS) was performed on RT-PCR positive samples.
Serology results were compared with those of six care homes with recognised outbreaks.
Findings: Across seven non-outbreak homes, 718 (387 staff, 331 residents) individuals had a nasal swab and
651 (386 staff, 265 residents) had follow-up serology. Sixteen individuals (13 residents, 3 staff) in five care
homes with no reported cases were RT-PCR positive (care home positivity rates, 0 to 7.6%) compared to 13
individuals (3.0 and 10.8% positivity) in two homes reporting a single case.
Seropositivity across these seven homes varied between 10.7-56.5%, with four exceeding community sero-
prevalence in London (14.8%). Seropositivity rates for staff and residents correlated significantly (rs 0.84,
[95% CI 0.51-0.95] p <0.001) across the 13 homes. WGS identified multiple introductions into some homes
and silent transmission of a single lineage between staff and residents in one home.
Interpretation: We found high rates of asymptomatic infection and transmission even in care homes with no
COVID-19 cases. The higher seropositivity rates compared to RT-PCR positivity highlights the true extent of
the silent outbreak.
Funding: PHE
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Care homes have been particularly affected by COVID-19, with
large outbreaks associated with high morbidity and mortality among
residents [14]. In England, the first imported cases of COVID-19
were confirmed at the end of January 2020. Cases started increasing
rapidly from early March 2020 and the first wave plateaued in mid-
Research in context
Evidence before this study
We searched PubMed with the terms “COVID-19” or “SARS-
CoV-2” and “care home”, “nursing home”, “nursing facility” or
“residential home” to identify publications relating to SARS-
CoV-2 infections and COVID-19 outbreaks since January 2020,
focusing particularly on enhanced outbreak investigations and
antibody testing. Mass swabbing identified high rates of symp-
tomatic and asymptomatic SARS-CoV-2 infections among resi-
dents and staff. There are limited investigations involving
antibody testing for evidence of prior exposure to SARS-CoV-2
or to assess immunity against the virus in residents or staff
members.
Added value of this study
We investigated the degree of exposure to SARS-CoV-2 in five
care homes with no reported or suspected cases of COVID-19
and two care homes with single cases. Swabbing for SARS-CoV-
2 RNA identified infection rates of 0 to 7.6% in care homes with
no cases, half of whom remained asymptomatic, and 3.0-10.8%
in homes reporting a single case. SARS-CoV-2 seropositivity
ranged between 10.7-56.5% in non-outbreak care homes. There
was a strong and significant correlation in seropositivity rates
between staff and residents across all the care homes investi-
gated (rs 0.84, p < 0.001).
Implications of all the available evidence
Given the high fatality rates associated with COVID-19 in care
home residents, regular screening with rapid isolation of
infected residents and staff may be the only effective option for
preventing SARS-CoV-2 infection and transmission in these
high-risk settings during the COVID-19 pandemic. Additionally,
serological investigations provide a more accurate assessment
of exposure in institutional settings and are critical for under-
standing of immune correlates of protection from reinfection
and to inform future vaccination policy.
2 A. Jeffery-Smith et al. / The Lancet Regional Health - Europe 3 (2021) 100038April 2020 before declining [5] At the peak of the pandemic, the large
number of COVID-19 outbreaks in care homes across London, one of
the earliest affected areas in the UK, prompted outbreak investiga-
tions by Public Health England (PHE). Initially, six care homes report-
ing an outbreak to the PHE London Coronavirus Response Centre
(LCRC) during 10-13 April 2020 were investigated with nasal swab-
bing of more than 500 residents and staff, with 45% of residents and
20% of staff found to be infected with SARS-CoV-2 (Phase 1) [4].
Around 80% of those infected were asymptomatic at the time of test-
ing and half never developed any symptoms throughout their infec-
tion. Further outbreak investigations were initiated one week later in
four care homes reporting only a single confirmed or suspected case
of COVID-19 (Phase 2). In two of these care homes the virus had
already spread extensively, affecting 32% and 61% of residents and
staff, respectively [6]. In the other two homes, however, only 3% and
11% tested positive for SARS-CoV-2 infection. Infected residents and
staff were isolated and stringent infection prevention and control
(IPC) practices were reinforced in all four homes. Repeat swabbing a
week later confirmed no further spread of the virus.
Here we report Phase 3 of the care home investigations which
aimed to assess the presence of silent infection and transmission in
five London care homes with no suspected or confirmed cases of
COVID-19 at the peak of the pandemic. In addition to the initialswabbing of all residents and staff, blood samples for SARS-CoV-2
antibodies were obtained in the five care homes with no evidence of
infection and two care homes with limited SARS-CoV-2 infection in
the second phase of the investigations. Evidence of virus exposure by
either nasal swab SARS-CoV-2 reverse transcription polymerase
chain reaction (RT-PCR) positivity or SARS-CoV-2 antibody positivity
were compared between these seven ‘non-outbreak’ homes and the
initial six outbreak homes [4,7].
2. Methods
2.1. Recruitment
The PHE public health response to understand the effects of the
COVID-19 pandemic on care homes involved enhanced surveillance
of care homes reporting different COVID-19 case profiles in London.
Six care homes, referred to as ‘outbreak’ homes, reporting at least
two confirmed or suspected COVID-19 cases to the PHE London
Health Protection Teams (HPTs) in early April 2020 were recruited
into the first phase of the London care home investigations [4]. A
week later, four care homes reporting a single case of suspected or
confirmed COVID-19 were investigated in the second phase of the
investigation;[6] two of these homes with low PCR positivity rates
(<15%) were subsequently recruited to follow-up serological assess-
ment. In the following week, care homes without any suspected or
confirmed cases of COVID-19 were identified by cross-referencing
the care home register held by the Care Quality Commission (CQC),
the independent regulator of health and social care in England, with
data held by local HPTs. The managers of these care homes were con-
tacted to confirm that no suspected or confirmed cases of COVID-19
had been identified previously in residents or staff. Five care homes
where the manager consented to participation on behalf of all their
residents and staff (those with and without regular contact with resi-
dents) were recruited in phase 3 of the investigation to undertake
nasal swab RT-PCR testing for SARS-CoV-2 and serum sampling. The
care homes had experienced nursing staff and were provided with
detailed written instructions for nasal swabbing. The staff swabbed
themselves and the residents in their respective care homes. Symp-
tom status during the 14 days before and at the time of swabbing
was collected for all staff, who self-reported any symptoms, and resi-
dents, whose symptoms were recorded the care home staff. Daily
interviews were undertaken with individual care homes to identify
any newly symptomatic individuals. Typical COVID-19 symptoms at
that time included fever 37.8⁰C, shortness of breath or cough, while
atypical symptoms included, but were not restricted to, new confu-
sion, reduced alertness, fatigue, lethargy, reduced mobility and diar-
rhoea. Serum samples were obtained a minimum of five weeks after
the initial nose swabs and were taken by nursing staff working in the
respective care homes. The five homes with no recognised cases and
two homes with single cases and PCR positivity <15% recruited to
serological follow-up are collectively referred to as ‘non-outbreak’
homes.
The investigation protocol was reviewed and approved by the PHE
Research Ethics and Governance Group. PHE has legal permission,
provided by Regulation 3 of the Health Service (Control of Patient
Information) Regulation 2002, to process patient confidential infor-
mation for national surveillance of communicable diseases. Verbal
consent for testing was obtained by care home managers from staff
members and residents or their next of kin as appropriate.
2.2. SARS-CoV-2 RT-PCR
Nucleic acid was extracted from samples and analysed by a previ-
ously described RT-PCR assay [8], targeting a conserved region of the
open reading frame (ORF1ab) gene of SARS CoV-2, together with
detection of an assay internal control to monitor the extraction and
A. Jeffery-Smith et al. / The Lancet Regional Health - Europe 3 (2021) 100038 3RT-PCR processes. This assay required 5mL RNA in a total RT-PCR
reaction volume of 25mL. Reverse transcription and PCR amplifica-
tion was performed on an Applied Biosystems 7500 FAST system.
2.3. SARS-CoV-2 antibody testing
Serum samples were tested for IgG to the SARS-CoV-2 nucleocap-
sid (N) protein using a commercial antibody test (Abbott) following
the manufacturer’s instructions and were also tested using an in-
house recombinant SARS-CoV-2 IgG spike (S) protein receptor bind-
ing domain (RBD) indirect ELISA (PHE). Briefly, 96 well microtiter
plates (Nunc, Cat-439454) coated with recombinant SARS-CoV-2 RBD
(Sino Biological Inc, Cat-40592-V05H) were blocked with phosphate
buffered saline solution with 5% milk, 1% bovine serum albumin and
0.05% Tween, and incubated with serum at 1:100 dilution. RBD spe-
cific IgG antibodies present in serum bound by the plate coated anti-
gen were detected using a polyclonal goat anti-human Fab secondary
antibody horseradish peroxidase conjugate (Sigma, Cat-A0293). The
sera were analysed in duplicate on each plate. Each plate also con-
tained at least one positive control human serum in duplicate, and a
negative human serum (true negative, collected prior to the pan-
demic), analysed in four wells. For analysis, mean optical density
(OD) values were calculated for each study serum, the controls and
negative sera. In-house RBD IgG results are presented as ratios of the
OD of the sample to the OD of the true negative (TN), analysed on the
same plate. OD/TN ratios of greater than or equal to 5.0 were consid-
ered positive. This cut-off value was determined through analysis of
ROC curves determined for a mixture of positive and negative sam-
ples (N positive 325, N negative 1431, N total 1756). Positive samples
were collected from individuals with PCR-confirmed SARS-CoV-2
infection, while negatives were collected before January 2020. The
cut-off resulted in a specificity of 98.1% (95% CI 97.3-98.8) and sensi-
tivity of 89.8% (95% CI 86.0-92.9). Qualitative results and index values
were used in analyses.
2.4. Whole genome sequencing
Whole genome sequencing (WGS) was performed on all RT-PCR
positive samples [9]. Viral amplicons were sequenced using Illumina
library preparation kits (Nextera) and sequenced on Illumina short-
read sequencing machines (Nextseq or Hiseq). The bioinformatics
protocol to generate consensus sequences utilised Trimmomatic,
BWA (mapping), and an in-house variant caller (quasibam) to align
against a SARS-CoV-2 reference genome (NC_045512.2). Consensus
sequences were generated using a depth cut-off of 20 reads and
ambiguities called where a minority variant detected at 20%, these
were aligned using MAFFT (Multiple Alignment using Fast Fourier
Transform, version 7.310), manually curated and maximum likeli-
hood phylogenetic trees derived using IQtree (version 2.04).
Genomes were included in analysis where the coverage of the refer-
ence genomes was 80%. Completed viral genomes were deposited
in GISAID (Supplementary Table 1) [10].
2.5. Statistical analysis
Descriptive analyses were performed. Continuous data that did
not follow a normal distribution were described as medians with
interquartile ranges and differences compared using the Mann-Whit-
ney U test. Seropositivity rates between outbreak and non-outbreak
care homes were also compared using Mann-Whitney U test. Concor-
dance of antibody positivity to N and S (RBD) protein was assessed
using McNemar’s test. Abbott SARS-CoV-2 IgG results are presented
as index values with medians and 95% confidence intervals (95% CI).
Antibody index values were compared using Kruskal-Wallis test.
Data were analysed using GraphPad Prism. Seropositivity rates werecompared to concurrent London community seroprevalence esti-
mates (adjusted prevalence, 14.8%) [11].
2.6. Role of the funding source
This study was funded by PHE. The authors had sole responsibility
for the study design, data collection, data analysis, data interpreta-
tion, and writing of the report. The authors are all employed by PHE,
the study funder, which is a public body — an executive agency of the
Department of Health and Social Care.
3. Results
3.1. Demographics
The timing of the investigations in these London care homes in
relation to reported outbreaks of acute respiratory illnesses and
COVID-19 related deaths in care homes across England is depicted in
Fig. 1. The seven non-outbreak care homes included five phase 3
homes with no reported or suspected cases of COVID-19 (A-E), and
two phase 2 homes with a single case (F and G). In total, 718 (387
staff, 331 residents) were investigated with a nasal swab for SARS-
CoV-2 RT-PCR at the first visit (timepoint T0) and 651 (386 staff, 265
residents) consented to SARS-CoV-2 antibody testing at follow-up
(T1), including 570 (87.6%) individuals (318 staff, 252 residents) who
also had the initial T0 nasal swab. One asymptomatic PCR positive
resident from the care homes with no reported cases died in the
week following the positive test; this individual had been receiving
end of life care in the preceding weeks. Two PCR positive residents
from the care homes with single cases died, one on the day of the
positive test and the other 11 days later. Both experienced COVID-19
symptoms prior to the test and the deaths were attributed to COVID-
19.
From the six phase 1 outbreak care homes (H-M), 586 (370 staff,
216 residents) consented to SARS-CoV-2 antibody testing at T1, 405
(69.1%) of whom (209 staff, 196 residents) had undergone nasal
swabbing for SARS-CoV-2 RT-PCR at T0. Across these six homes, 23
residents died during the five-week interval between RT-PCR and
serological testing, including 19 who had been SARS-CoV-2 RT-PCR
positive at a median of 4 (IQR 2 to 8) days prior to death.
3.2. Care home characteristics
Between the non-outbreak (N=7) and outbreak (N=6) homes,
there were no differences in the number of beds, percentage occu-
pancy or number of staff. All six outbreak care homes were nursing
care homes providing a range of specialty support, compared to four
of the seven non-outbreak care homes (Table 1). Using criteria
applied by regulators of care homes, there were no differences in the
characteristics of the care homes or case mix (Table 1).
3.3. RT-PCR positivity in care homes without reported cases of
COVID-19
Across the five care homes (A-E) with no reported COVID-19
cases, nasal swabbing identified 16 SARS-CoV-2 RT-PCR positive indi-
viduals (13 residents, 3 staff). Eight (1 staff, 7 residents) reported
symptoms during the follow-up period, having been asymptomatic
at the time of testing. RT-PCR positive individuals had cycle threshold
values ranging between 21 and 37 (median, 35). SARS-CoV-2 RT-PCR
positivity rates ranged between 0% and 7.6% across these five care
homes (Table 2). Care home B had no SARS-CoV-2 RT-PCR positive
individuals, while two care homes (A and C) had SARS-CoV-2 RT-PCR
positive residents, but no staff positive. Repeat nasal swabs taken a
week later from 14 of the RT-PCR positive individuals (range 3-10
Fig. 1. Schematic of care home acute respiratory outbreaks (ARI; blue bars) and total COVID-19 related deaths in care homes in England (pink line) and London (yellow line)
reported by ISO week of 2020. The enhanced outbreak testing periods for nasal swabbing SARS-CoV-2 RT-PCR - time-point 0 (T0) - and serology for SARS-CoV-2 antibodies  time-
point 1 (T1) - are indicated for the care homes with outbreaks (phase 1 - red), single cases (phase 2 - amber) and those with no reported cases (phase 3 - green).
4 A. Jeffery-Smith et al. / The Lancet Regional Health - Europe 3 (2021) 100038days) found that four (28.6%) remained positive. None were positive
two weeks later (15-19 days after the first swab).3.4. SARS-CoV-2 seropositivity in care homes independent of outbreak
profile
Seropositivity rates were significantly lower in the non-outbreak
care homes (A-G) compared to the outbreak homes (H-M) (median
seropositivity 30.3% vs. 74.7%; Mann-Whitney U test p=0.0047).
Between individual care homes, however, seropositivity rates were
highly variable, with seropositivity ranging from 10.7% to 56.5% in
care homes A-G and from 41.9% to 84.0% in care homes H-M (Table 2).
Four of the non-outbreak care homes (A, C, D, E) and all the outbreak
care homes had seropositivity rates exceeding the community esti-
mated seroprevalence in London at the time of the investigationTable 1
Care home characteristics.
Care home Type of care (CQC) Bedsz Occupancy (%) No. staff Registered Care Categ
A Residential 50 92.3 30 Dementia
B Nursing 60 88.3 78* Dementia, old age
C Residential 50 86.7 58 Dementia, old age
D Nursing 110 40.4 45 Dementia, old age, se
E Nursing 60 79.7 69 Dementia, eating diso
tion, old age, physi
misuse
F Residential 50 87.8 34 Dementia, learning d
G Nursing 60 85.0 106 Old age, physical disa
H Nursing 100 90.0 135 Dementia, mental he
I Nursing 80 76.9 85 Dementia, old age
J Nursing 90 84.7 110 Dementia, mental he
sory impairment
K Nursing 40 90.7 14 Old age
L Nursing 60 90.6 70 Dementia, old age
M Nursing 50 57.1 65 Old age
* minimum number of staff; NS = not specified. Colour coding: red = outbreak reported;
Care Quality Commission.
y Care homes in the UK are regulated by the CQC. Registration with the CQC includes a des
z Rounded to the nearest 10, analysis has been performed on exact numbers.(14.8%). In contrast, care homes B, F and G had seropositivity rates
around or below the community seroprevalence, but with seroposi-
tivity in both staff and residents within the care homes (Fig. 2).3.5. Seroconversion in SARS-CoV-2 RT-PCR positive staff and residents
Of the 187 SARS-CoV-2 RT-PCR positive individuals (60 staff, 127
residents) across the 13 London care homes, 130 (48 staff, 82 resi-
dents) had follow-up serology, including 126 (96.9%) individuals (47
staff, 79 residents) who seroconverted a median 36 days (IQR 35 to
38) after their positive SARS-CoV-2 RT-PCR nasal swab. Within this
cohort, 116 (92.1%; 45 staff, 71 residents) had detectable SARS-CoV-2
antibodies to the N protein and 123 (97.6%; 47 staff, 76 residents) to
S protein in the RBD assay (McNemar’s test of difference between N
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amber  single case reported; green = no cases reported at time of investigation. CQC:
cription of the care categories offered by the home.
Table 2
Relationship of SARS-CoV-2 PCR positivity on nasal swab at T0 to convalescent IgG positivity to nucleocapsid (N) protein (Abbott) at
T1.
PCR positive (%) PCR positive seropositive N(%) PCR negative seropositive N(%) Total seropositive N (% [95% CI])
A 4/91 (4.4) 2/3 (66.7) 16/57 (28.1) 20/66
(30.3 [20.6 to 42.2])
B 0/124 (0.0) NA 12/112 (10.7) 14/129
(10.9 [6.6 to 17.4])
C 1/90 (1.1) 1/1 (100) 22/66 (33.3) 23/70
(32.9 [23.0 to 44.5])
D 7/92 (7.6) 3/4 (75) 30/52 (57.7) 39/69
(56.5 [44.8 to 67.6])
E 4/104 (3.8) 4/4 (100) 42/84 (50.0) 53/107
(49.5 [40.2 to 58.9])
F 9/83 (10.8) 5/5 (100) 6/67 (9.0) 14/79
(17.7 [10.9 to 27.6])
G 4/134 (3.0) 1/1 (100) 12/114 (10.5) 14/131
(10.7 [6.5 to 17.1])
H 35/94 (37.2) 13/15 (86.7) 21/36 (58.3) 59/90
(65.9 [55.3 to 74.6])
I 14/72 (19.4) 9/11 (81.8) 31/45 (69.9) 58/84
(68.3 [57.6 to 77.4])
J 23/98 (23.5) 15/17 (88.2) 61/73 (83.6) 124/153
(81.0 [74.1 to 86.5])
K 47/74 (63.5) 36/39 (92.3) 15/22 (68.1) 63/75
(84.0 [74.1 to 90.6])
L 18/97 (18.6) 13/14 (92.9) 24/71 (33.8) 49/117
(41.9 [33.3 to 50.9])
M 21/83 (25.3) 14/16 (87.5) 39/46 (84.8) 56/67
(83.6 [72.9 to 90.6])
Total seropositivity includes individuals who did not have PCR at T0. The previously reported SARS-CoV-2 RT-PCR positivity for care
homes F and G is shown for comparison.6 A subset of results for care homes H-M were included in a previous publication.4 NA: not
applicable.
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Seropositivity rates for staff and residents in non-outbreak care
homes (amber and green) were significantly lower than those of out-
break care homes (red); the Mann-Whitney U test for staff seroposi-
tivity between outbreak and non-outbreak homes was p=0.0047 and
for residents was p=0.014) (Fig. 2a). Within the 13 homes, there was
a strong and significant correlation in seropositivity rates for staff
and resident (rs 0.84, [95% CI 0.51-0.95] p<0.001) (Fig. 2b).3.7. Seropositivity by age
SARS-CoV-2 seropositivity rates did not differ by age in non-out-
break care homes (Kruskal-Wallis test p=0.84) or outbreak care
homes (Kruskal Wallis test p=0.72) (Fig. 3a). Across all thirteen care
homes there was no significant difference in reactivity to the N basedFig. 2. a) Summary data showing percentage IgG seropositivity against SARS-CoV-2 nucleoca
and residents (right panel) for each care home (A-M). Dashed line indicates coincident estima
positivity for each of the 13 care homes (Spearman rank correlation coefficient 0.84, p < 0.0
case reported; red = outbreak reported. Red defined as ‘outbreak’ homes; Amber and green hassay by age for seropositive individuals (Kruskal Wallis test p=0.30)
(Fig. 3b).
3.8. Genomics analysis of non-outbreak care homes
The 29 SARS-CoV-2 RT-PCR positive samples from the seven non-
outbreak care homes (16 from care homes A-E, and 13 from care
homes F-G) taken at time T0 underwent WGS, with 21 samples yield-
ing whole genome sequences (Supplement Table 1). Different SARS-
CoV-2 lineages were identified in different care homes (Fig. 4). Care
home F had evidence of more than one introduction of SARS-CoV-2
into the home and findings consistent with onward local transmis-
sion between staff and residents as demonstrated by identical
sequences in 3 residents and 2 staff (Fig. 4). Care homes A, C and G
showed strains that were identical or differing by one or two single
nucleotide polymorpshisms in at least two residents; local transmis-
sion cannot be inferred or excluded on the basis of these results.psid (N) protein (Abbott) and 95% confidence intervals for care home staff (left panel)
ted community seroprevalence in London [11]. b) Correlation of resident and staff sero-
01). Colour coding: green = no cases reported at time of investigation; amber = single
omes defined as ‘non-outbreak’ homes.
Fig. 3. a) Summary data showing IgG serostatus to SARS-CoV-2 N protein by age for non-outbreak care homes (left panel, N=651) and outbreak care homes (right panel, N=586). Sta-
tistical analysis using Kruskal-Wallis test non outbreak homes p=0.84. Statistical analysis using Kruskal-Wallis test outbreak homes p=0.58. b) Summary data showing SARS-CoV-2
recombinant N IgG index value (Abbott) for all seropositive individuals (n=586) for all care homes. Kruskal Wallis test p=0.30. Age bracket of <60 applied to encompass majority of
staff. Categories of 60-84 and 85 applied to separate residents based on frequency distribution of age of residents from across the cohort and mean age of 85 years.
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In addition to widespread infection and transmission of SARS-
CoV-2 in care homes reporting an outbreak of COVID-19 and in care
homes reporting a single suspected or confirmed case of COVID-19
during the peak of the pandemic in London, England, we foundFig. 4. Maximum likelihood phylogeny of 21 SARS-CoV-2 genomes from individuals
across the six non-outbreak care homes with PCR positive individuals. Coloured shapes
are used to indicate the care home, with circles denoting residents and triangles staff.
The phylogenetic tree was rooted using the midpoint of the phylogeny.infections in all five care homes that reported no cases or outbreaks
of COVID-19 (A-E). Serological testing provided a more complete pic-
ture of the extent of virus spread in the non-outbreak care homes,
with seropositivity rates ranging between 10.7% to 56.5% compared
to SARS-CoV-2 RT-PCR positivity of 0 to 7.6%. These care homes
reported no cases or outbreaks since the start of the pandemic
despite heightened awareness of staff in these settings, and none of
the residents were symptomatic when swabbed at T0. This, together
with the high correlation in seropositivity rates between staff and
residents within individual care homes and supported by WGS analy-
sis, highlights the ability of SARS-CoV-2 to enter care homes and
spread silently between staff and residents.
The variable seropositivity among staff and residents high-
lights the wide-ranging impact of SARS-CoV-2 on care homes. In
particular, seropositivity rates among residents in homes A, C, D
and E were as high as those reported in the care homes that
experienced large outbreaks. Interestingly, though, there were
very few deaths among residents in care homes A, C, D, E during
the surveillance period. This may be a consequence of lower
case-fatality rates associated with asymptomatic infection com-
pared to symptomatic disease, as we have recently reported,
although the reasons for predominance of asymptomatic or mild
disease in this cohort remains unclear [4]
In contrast, residents in care homes B, F and G had seropositivity
rates around or below the levels observed in the community. It is
possible these care homes were in the early stages of an outbreak
and that nasal swabbing as part of the care home investigation led to
rapid identification and isolation of infected residents and staff mem-
bers with reinforcement of IPC measures by the PHE investigation
team, thus limiting the spread of the virus within the care homes
[4,12]
Asymptomatic infection is now well-recognised as a manifes-
tation of SARS-CoV-2 infection, although the proportion of
asymptomatic infections reported is highly heterogenous across
different populations and settings [1317] The role of asymptom-
atic individuals in SARS-CoV-2 transmission remains unclear, but
the finding of asymptomatic SARS-CoV-2 infection in care homes
that did not report a single case of COVID-19 and genomic evi-
dence of a small cluster of staff and residents infected with the
same SARS-CoV-2 lineage in care home F provides strong evi-
dence for silent transmission among asymptomatic residents and
staff. This is also supported by the higher seropositivity rates
compared to RT-PCR positivity in all the investigated care homes,
confirming widespread asymptomatic infection and transmission
throughout the course of the pandemic.
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CoV-2 infection and antibody positivity rates between care homes,
[18,19] but in our small but intensively investigated cohort we did
not observe any significant differences in care home size, number of
beds or staff numbers between the outbreak and non-outbreak
homes. In addition, analysis of the CQC reports for these care homes
did not highlight issues with IPC measures between the outbreak and
non-outbreak homes. The six care homes that experienced large
COVID-19 outbreaks, however, all provided nursing care compared
to three of the seven non-outbreak care homes. Possible explanations
include the level of care required for residents in nursing homes pre-
cluded effective IPC practices and residents had a higher risk of hospi-
talisation because of their underlying medical conditions. Early in the
pandemic when there was limited testing for SARS-CoV-2, hospital-
ised residents returning to their care homes were considered a signif-
icant source of SARS-CoV-2 introduction. Contact patterns and
behaviours inside and outside the care home are also likely to have
contributed to the introduction and spread of SARS-CoV-2 in care
homes, especially in the early pandemic phase when there were no
restrictions of movement for staff, residents or visitors; this was not
assessed as part of this investigation.
5. Strengths and limitations
The strength of these early, systematic and progressive care home
investigations at the peak of the pandemic in London is the timeliness
of the investigations and the comprehensive outcome follow-up. One
limitation is that, because there was no testing for SARS-CoV-2 in
care homes at the time, we had limited data information on potential
cases or deaths in care homes reporting a case or an outbreak of
COVID-19 before we began our investigations. Additionally, because
of the large number of residents and staff investigated, we also did
not collect extensive individual-level information such as co-morbid-
ities, range and duration of individual symptoms or contact patterns
between residents and staff. We used PCR testing to estimate the
point prevalence of SARS-CoV-2 infection with the knowledge that
its performance and utility is dependent on swabbing technique, tim-
ing of sampling in relation infection and assay performance [20]
Another limitation was that, because serological tests were not avail-
able at the time, we did not collect blood samples at the initial inves-
tigation which would have allowed assessment of baseline
seropositivity and assessment of seroconversion. Finally, only staff
working in the care home at the time of testing were included at
each time point; as such, those who were self-isolating at home in
care homes with identified cases and outbreaks, or those not on shift
at the time of testing were not included in the investigation.
6. Implications and conclusions
The high SARS-CoV-2 seropositivity rates among staff and resi-
dents in care homes with no recognised COVID-19 outbreaks demon-
strates a significant role for asymptomatic infection leading to
widespread silent transmission within care homes and highlights the
futility of symptom-based screening. Following the London care
home investigations, national guidelines have been implemented to
recommend mass SARS-CoV-2 RT-PCR testing of care home staff and
residents at regular intervals. This strategy will increase detection of
asymptomatic infection, but may lead to false positive RT-PCR results,
especially during periods of low community infection rates [2022]
Access to point of care devices to rapidly identify highly infectious
individuals may alleviate some of the disruption care homes are cur-
rently experiencing. Ongoing investigations in the London care
homes offer a unique opportunity to understand factors contributing
to the varying outcomes between similar high-risk populations
[1,18,23] Follow-up investigations are planned to inform the longev-
ity of antibody responses and the role of cellular immunity, whileregular RT-PCR screening will detect SARS-CoV-2 infections and help
with our understanding of the risk and frequency of re-infections in
care home residents and staff. These data will be critical for informing
vaccine strategy in this highly vulnerable group.
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